Evidence map›Paper›PMID 40691637›Full record

ArticleJournal of hematology & oncology2025

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study.

Eleonora Roncaglia, Enrico Gaffo, Giulia Calabretto, Moritz Fürstenau, Kerry A Rogers, Panagiotis Baliakas, Chenghua Cui, Cecelia Miller, Claudia Haferlach, Karla Plevova and 42 more

Abstract readLetter
In one paragraph

Article in Journal of hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Eleonora Roncaglia *Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
Enrico Gaffo *Department of Molecular Medicine, University of Padua, Padova, Italy.
Giulia CalabrettoHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Moritz FürstenauDepartment I of Internal Medicine, University of Cologne, Cologne, Germany.
Kerry A RogersThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Panagiotis BaliakasDepartment of Immunology, Genetics and Pathology & Clinical Genomics Uppsala, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Chenghua CuiState Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Institutes of Health Science, Tianjin, China.
Cecelia MillerThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Karla PlevovaDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University, Brno, Czech Republic.
David OscierMolecular Pathology, University Hospitals Dorset, Royal Bournemouth Hospital, Bournemouth, UK.
Zadie DavisMolecular Pathology, University Hospitals Dorset, Royal Bournemouth Hospital, Bournemouth, UK.
Florence Nguyen-KhacService d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Paris, France.
Gian Matteo RigolinHematology Section, Department of Medical Sciences, Arcispedale S. Anna, Azienda Ospedaliera-Universitaria, University of Ferrara, Ferrara, Italy.
Anastasia AthanasiadouHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Fanny Baran-MarszakLaboratoire d'hématologie, Hôpital Avicenne, Assistance Publique- Hôpitaux de Paris, Paris, France.
Alberto ValienteServicio de Genética, Hospital Universitario de Navarra, Pamplona, Spain.
Maria José TerolServicio de Hematología y Oncología Médica, Hospital Clinico Universitario de Valencia, Valencia, Spain.
Pau AbrisquetaDepartment of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Blanca EspinetMolecular Cytogenetics Laboratory, Pathology Department, Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar, Hospital del Mar Research Institute, Barcelona, Spain.
Anna PuiggrosMolecular Cytogenetics Laboratory, Pathology Department, Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar, Hospital del Mar Research Institute, Barcelona, Spain.
Annalisa MartinesImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padova, Italy.
Laura BonaldiImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padova, Italy.
Francesca Romana MauroDepartment of Translational and Precision Medicine, Hematology Unit, 'Sapienza' University, Rome, Italy.
Lydia ScarfòMedical School, Università Vita-Salute San Raffaele, Milano, Italy.
Thomas ChatzikonstantinouInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Eugen TauschUlm University, Ulm, Germany.
Karl-Anton KreuzerDepartment I of Internal Medicine, University of Cologne, Cologne, Germany.
Arnon KaterDepartment of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.
Francesc BoschDepartment of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Michael DoubekDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Panagiotis PanagiotidisFirst Department of Propaedeutic, University of Athens, Athens, Greece.
Olga KalashnikovaFederal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation, St. Petersburg, Russia.
Federica FrezzatoHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Valeria RuoccoHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Silvia OrsiHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Kimia SalekDepartment of Molecular Medicine, University of Padua, Padova, Italy.
Roberto MerloComputational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
Alberto CaregariComputational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
Ilias GlogovitisDepartment of Molecular Medicine, University of Padua, Padova, Italy.
Alessandro CelliniHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Francesco AngotziHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Andrea SerafinHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Shuhua YiState Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Institutes of Health Science, Tianjin, China.
Barbara EichhorstDepartment I of Internal Medicine, University of Cologne, Cologne, Germany.
Jennifer A WoyachThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Antonio CuneoHematology Section, Department of Medical Sciences, Arcispedale S. Anna, Azienda Ospedaliera-Universitaria, University of Ferrara, Ferrara, Italy.
Paolo GhiaMedical School, Università Vita-Salute San Raffaele, Milano, Italy.
Kostas StamatopoulosInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Livio TrentinHematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy.
Andrea Visentin *Hematology Unit, Department of Medicine, University of Padua, via N Giustiniani 2, 35128, Padova, Italy. andrea.visentin@unipd.it.
Stefania Bortoluzzi *Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.

Funding

Fondazione AIRC per la ricerca sul cancro ETS IG 2017 #20052Fondazione AIRC per la ricerca sul cancro ETS IG-25024National Center for HPC, Big Data and Quantum Computing CN00000013ONLUS'Ricerca per Credere nella Vita' (RCV) odv DIMED-LT2024PNRR "National Center for Gene Therapy and Drugs based on RNA Technology" CN00000041PRIN MIUR 2022 #20222EC7LAProgetti di Rilevanza Nazionale PRIN PNRR P2022PSMX4Supporting Talent in ReSearch@University of Padua - Starting Grant Be Be_CL3VERTowards Precision Medicine: Advanced cellular analytics in biomedical research-PureCell, funded by the Hellenic Foundation for Research and Innovation under the 1st call for research projects EL.ID.EK. for FacultyMembers and researchers and the supply of high-value research equipment EL.ID.EK
6 · The paper itself

Abstract

In Chronic Lymphocytic Leukemia (CLL), t(14;19)(q32;q13), leading to the overexpression of BCL3, is found in ∼1% of cases and is associated with an aggressive disease. In this study, leveraging a large CLL patient cohort collected thanks to an international collaboration, we investigate for the first time the circular transcriptome (circRNAome) associated with the rare t(14;19), in comparison with CLL without t(14;19) and B cells of age-matched healthy donors. We described the circRNAs commonly dysregulated in CLL, including circCSNK1G3 and circEXOC6B(3–5), which were depleted, and circZNF609 and circLPAR3, which were overexpressed in malignant cells. Of importance, we disclosed the circRNA signature of CLL with t(14;19), formed by circRNAs with expression significantly altered specifically in link with this lesion, ectopically expressed like circCDK14(3–4), circCORO1C, circCLEC2D, and circEMB, or downregulated like circCEP70(3–6). Several of these molecules were previously shown to be dysregulated or play a role in cancer, whereas most of the signature circRNAs deserve further investigation. CLL patients with high circCORO1C and circCLEC2D expression had significantly worse clinical outcomes, with shorter time to first treatment and overall survival. This study disclosed new molecular features of the aggressive CLL subtype with t(14;19).

Indexed as

Chromosomes, Human, Pair 14Chromosomes, Human, Pair 19Leukemia, Lymphocytic, Chronic, B-CellRNA, CircularTranslocation, GeneticAgedFemaleHumansMaleTranscriptomeRNA, CircularBCL3Circular RNACLLT(14;19)

Identifiers

PMID40691637
PMCPMC12281749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.